## Eric S Daar

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8081630/publications.pdf

Version: 2024-02-01

758635 610482 1,383 27 12 24 citations h-index g-index papers 81 81 81 1756 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19. Annals of Internal Medicine, 2021, 174, 1151-1158.	2.0	16
2	Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. New England Journal of Medicine, 2021, 385, 595-608.	13.9	359
3	280. Burden of Hyperglycemia in Patients Receiving Dexamethasone for Severe COVID-19. Open Forum Infectious Diseases, 2021, 8, S245-S246.	0.4	O
4	Realâ€Time and Wireless Assessment of Adherence to Antiretroviral Therapy With Coâ€Encapsulated Ingestion Sensor in <scp>HIV</scp> â€Infected Patients: A Pilot Study. Clinical and Translational Science, 2020, 13, 189-194.	1.5	16
5	Myocardial Steatosis Among Antiretroviral Therapy–Treated People With Human Immunodeficiency Virus Participating in the REPRIEVE Trial. Journal of Infectious Diseases, 2020, 222, S63-S69.	1.9	17
6	Progressive brain atrophy in chronically infected and treated HIV+ individuals. Journal of NeuroVirology, 2019, 25, 342-353.	1.0	26
7	Relationships Between Adipose Mitochondrial Function, Serum Adiponectin, and Insulin Resistance in Persons With HIV After 96 Weeks of Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 358-366.	0.9	7
8	Safety and Impact of Low-dose Methotrexate on Endothelial Function and Inflammation in Individuals With Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314. Clinical Infectious Diseases, 2019, 68, 1877-1886.	2.9	42
9	Two-drug regimens for treatment of naïve HIV-1 infection and as maintenance therapy. Drug Design, Development and Therapy, 2018, Volume 12, 3731-3740.	2.0	22
10	CD8+Cytotoxic T Lymphocyte Responses and Viral Epitope Escape in Acute HIV-1 Infection. Viral Immunology, 2018, 31, 525-536.	0.6	2
11	Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. Pharmacogenetics and Genomics, 2018, 28, 179-187.	0.7	4
12	Trajectories and Predictors of Longitudinal Preexposure Prophylaxis Adherence Among Men Who Have Sex With Men. Journal of Infectious Diseases, 2018, 218, 1551-1559.	1.9	28
13	HIV viral kinetics and T cell dynamics in antiretroviral naà ve persons starting an integrase strand transfer inhibitor and protease inhibitor regimen. HIV Clinical Trials, 2017, 18, 67-74.	2.0	3
14	Emtricitabine + tenofovir alafenamide for the treatment of HIV. Expert Opinion on Pharmacotherapy, 2017, 18, 427-432.	0.9	10
15	Phase 3 Randomized, Controlled Trial of Switching to Fixed-dose Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) from Boosted Protease Inhibitor-based Regimens in Virologically Suppressed Adults: Week 48 Results. Open Forum Infectious Diseases, 2017, 4, S735-S735.	0.4	3
16	Novel approaches to HIV therapy. F1000Research, 2017, 6, 759.	0.8	9
17	Condomless Sex With Virologically Suppressed HIV-Infected Individuals. JAMA - Journal of the American Medical Association, 2016, 316, 149.	3.8	7
18	Individualized diagnosis interventions can add significant effectiveness in reducing human immunodeficiency virus incidence among men who have sex with men: insights from Southern California. Annals of Epidemiology, 2015, 25, 1-6.	0.9	20

#	Article	IF	Citations
19	Antiretroviral Therapy. Infectious Disease Clinics of North America, 2014, 28, 439-456.	1.9	9
20	Impaired Nef Function Is Associated with Early Control of HIV-1 Viremia. Journal of Virology, 2014, 88, 10200-10213.	1.5	33
21	Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1. Annals of Internal Medicine, 2011, 154, 445.	2.0	287
22	Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202. Journal of Infectious Diseases, 2011, 203, 1791-1801.	1.9	435
23	New approaches and resolve may define the future of the global HIV pandemic. Research Initiative, Treatment Action: RITA, 2007, 12, 8-10.	0.1	О
24	Human immunodeficiency virus and fertility care: embarking on a path of knowledge and access. Fertility and Sterility, 2006, 85, 298-300.	0.5	14
25	Reply to Antonucci et al Journal of Infectious Diseases, 2005, 192, 704-705.	1.9	4
26	Improving adherence to antiretroviral therapy. Aids Reader, 2003, 13, 81-2, 85-6, 88-90.	0.3	9
27	Antiretroviral resistance in clinical practice. Journal of the International Association of Providers of AIDS Care, 2003, 2 Suppl 1, S4-18.	1.2	O